FDA Grants Accelerated Approval to Tovorafenib for Pediatric Patients With BRAF-Mutated LGG
Tovorafenib is the first systemic therapy to be approved for the treatment of pediatric patients who have low-grade glioma with BRAF rearrangements or fusions.
Eric Bouffet Roger Packer Day One Biopharmaceuticals Inc Behavioral Medicine At Children National Hospital Us Food Drug Administration Alex Mit
Source: pharmacytimes.com